Development · 28 Aug 2026
4 publishers have reported this development. Each act of reporting is below, cited.
Aragen Life Sciences filed its draft red herring prospectus with the Securities and Exchange Board of India for an initial public offering comprising a fresh issue of equity shares worth ₹800 crore and an offer for sale of up to 27,329,192 equity shares by existing shareholders.
Aragen Life Sciences filed draft papers with SEBI to raise ₹800 crore through an initial public offering, with an offer for sale of 2.73 crore equity shares by selling shareholders including promoters and Goldman Sachs Capital Holdings.
Aragen Life Sciences filed Draft Red Herring Prospectus with SEBI for an IPO comprising a fresh issue of Rs 800 crore and offer for sale of up to 2.7 crore equity shares.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.